Grupo para la caracterización molecular de las neoplasias hematológicas
![Foto de Grupo para la caracterización molecular de las neoplasias hematológicas](/img/grupo.png)
![Foto de University of Milan](/img/noimage_org.png)
University of Milan
Milán, ItaliaPublicaciones en colaboración con investigadores/as de University of Milan (6)
2023
-
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023
Hematological oncology
-
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 279-288
2021
-
Cereblon enhancer methylation and IMiD resistance in multiple myeloma
Blood, Vol. 138, Núm. 18, pp. 1721-1726
-
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 801-812
-
Pathogenetic and prognostic implications of increased mitochondrial content in multiple myeloma
Cancers, Vol. 13, Núm. 13
2018
-
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study
Haematologica, Vol. 103, Núm. 7, pp. 1209-1217